Abstract
Asthma is characterized by pathological airway remodeling resulting from persistent myofibroblast activation. Although transforming growth factor beta 1 (TGFβ1), mechanical signals, and reactive oxygen species (ROS) are implicated in fibroblast differentiation, their integration is still elusive. We identified that Transient Receptor Potential Vanilloid 4 (TRPV4), a mechanosensitive ion channel mediates lung fibroblast (LF) differentiation and D. farinae-induced airway remodeling via a novel TRPV4-NADPH Oxidase 4 (NOX4) interaction. NOX4-mediated ROS production is essential for TGFβ1-induced LF differentiation via myocardin-related transcription factor-A (MRTF-A) and plasminogen activator inhibitor 1 (PAI-1). Importantly, TRPV4 inhibition prevented TGFβ1-induced NOX4 expression and ROS production. Both TRPV4 and NOX4 are activated by phosphatidylinositol 3-kinase (PI3K) downstream of TGFβ1, and signals from both TRPV4 and Rac are necessary for NOX4 upregulation. Notably, NOX4 expression is higher in fibroblasts derived from asthmatic patients (disease human LF; DHLF) in comparison to non-asthmatics (normal human LF; NHLF). Further, NOX4 expression is up-regulated in the lungs of D.farinae-treated wild type mice (WT) relative to saline-treated WT, which was attenuated in TRPV4 knockout (KO) mice. Our findings suggest that TRPV4 integrates TGFβ1 and ROS signaling through NOX4 and, TRPV4-NOX4 interaction is amenable to target lung remodeling during asthma.
Similar content being viewed by others
Introduction
Asthma is characterized by inflammation, eosinophilic infiltration, bronchial hyperresponsiveness1,2, and significant airway remodeling3,4. In fact, airway remodeling due to excessive extracellular matrix (ECM) deposition has been shown to be responsible for the rapid decline in lung function experienced in the treatment of resistant asthmatics compared to non-asthmatics5. While airway inflammation is known to play a role in the progression of airway remodeling, the mechanisms regulating this process remain poorly understood. In asthmatics, susceptibility to injury and aberrant repair responses result in persistent activation of fibroblasts, differentiating them into myofibroblasts6. Myofibroblasts are hyper-secreting, contractile cells that facilitate wound healing through increased ECM synthesis7,8,9. Disproportionate ECM production and prolonged survival of myofibroblasts can lead to pathological fibrosis10,11,12. Soluble factor, Transforming Growth Factor beta 1 (TGFβ1), has been identified as a major player in the differentiation of fibroblasts to myofibroblasts and lung remodeling. However, the downstream signaling pathways and their intersection is still not completely understood.
TGFβ1 promote fibroblast differentiation by enhancing fibrotic and ECM components13, leading to abnormal mechanical properties. Mechanical rigidity is also a causal factor in myofibroblast differentiation, compromising lung function14. Transient Receptor Potential Vanilloid 4 (TRPV4) is a mechanosensitive ion channel that has been shown to regulate lung function15 and airway hyperresponsiveness in patients with asthma16, cardiac17 and lung18 fibrosis. Employing a model of Dermatophagoides farinae (D.farinae)-induced asthma, we recently reported that TRPV4 KO mice were protected from D.farinae -induced airway remodeling19.
Interestingly, in addition to soluble and mechanical signals, enhanced ROS production was well documented in asthma with high levels of superoxide generated by nicotinamide adenine dinucleotide phosphate (NADPH) oxidases (NOX)20. Although the NOX family includes seven members (NOX1, NOX2, NOX3, NOX4, NOX5, Duox1 and Duox2), TGFβ1-mediated fibroblast differentiation has been shown to be regulated by NOX421 in LF. Unlike other NOX isoforms, NOX4 has been suggested to be constitutively active and is regulated at the level of expression. Notably, NOX4 expression and activity (ROS production) is demonstrated to be a driving force for fibroblast differentiation21,22 and lung fibrosis21. However, the mechanism by which NOX4 expression is enhanced in asthmatic airway remodeling remains unclear. Although soluble, mechanical and redox pathways are implicated in fibroblast differentiation and lung remodeling, little is known regarding their integration and contribution to asthma. Here, we demonstrate that NOX4 integrates TGFβ1 and mechanical signaling in fibroblast differentiation and lung remodeling during asthma.
Materials and Methods
Animals
C57BL/6J mice (Jackson Laboratories) and TRPV4 KO mice on C57BL/6 background23 were maintained at the Comparative Medicine Unit at Northeast Ohio Medical University (NEOMED). All animal experiments were done in accordance with standard guidelines as approved by the Animal Care and Use Committee of NEOMED.
Reagents
The following chemicals and reagents were purchased commercially: RN1734 (selective TRPV4 inhibitor)17,24, EHT 1864 (selective Rac inhibitor)25, (Tocris Bioscience, Minneapolis, MN), LY294002 (PI3K inhibitor)26,27 (Cayman Chemicals, Ann Arbor, MI), TGFβ1 (R&D Systems, Minneapolis, MN), PAI-1 antibody (Ab) (Cell Signaling Technology, Danvers, MA), Diphenyleneiodonium chloride (DPI; NOX inhibitor), N-Acetyl Cysteine (NAC; antioxidant)28, alpha smooth muscle actin (α-SMA) Ab (Sigma- Aldrich, St Louis, MO), Amplex Red (Thermo Fisher Scientific, Waltham, MA, USA), Fibronectin (FN) Ab (Abcam, Cambridge, MA), Myocardin-Related Transcription Factor-A (MRTF-A) Ab (Santa Cruz Biotechnology Santa Cruz, CA), glyceraldehyde-3-phosphate dehydrogenase (GAPDH) Ab (Fitzgerald, Acton, MA), all secondary Abs (Jackson ImmunoResearch, West Grove, PA), non-targeting small interfering RNA (siRNA) and specific siRNA for TRPV4 and NOX4 (Dharmacon, Lafayette, CO), siLentFect lipid reagent (Bio-Rad, Hercules, CA), transcriptor first strand cDNA synthesis kit and light cycler 480 SYBR Green I Master Mix (Roche, Indianapolis, IN).
D. farinae induced airway remodeling
House dust mite (D. farinae) protein extract was purchased from Greer Laboratories (Lenoir, NC). D. farinae extract was resuspended in phosphate buffer saline (PBS) (Corning, NY) at a concentration of 2 mg/mL. Following isofluorane, 6–8 week old WT and TRPV4 KO mice received D.farinae (25 μg/animal) or saline intranasally, 3 times a week for 5 weeks. Mice were euthanized 24 h after the last intranasal instillation. RNA was isolated from the lungs and real time quantitative PCR (qPCR) was performed to analyze NOX4 transcript.
Broncho alveolar lavage (BAL) fluid was collected and cellular content was analyzed. After BAL fluid was collected, total cell number was determined by trypan blue staining. Differential cell count was obtained using Diff Quik Stain Set (Siemens, Newark, DE). Briefly, BAL fluid was cytospun (Cytospin, Thermo Fisher Scientific, Waltham, MA) onto glass slides, and stained with Diff Quik Stain Set according to the manufacturer’s protocol. A minimum of 300 cells were counted, and identified as macrophages, lymphocytes, or polymorphonuclear leukocytes (PMNs- eosinophils and neutrophils) based on morphological criteria. Lungs from mice were embedded in paraffin, sectioned, and stained for periodic Acid Schiff (PAS) to visualize goblet cells.
Cell culture
Validated primary normal human LF (NHLF) (CC-2512) and diseased (asthma; Male, 27 years old, diagnosed at age 7 and on medication (Proventil, Albuterol)) human LF (DHLF) (00194912) were obtained from LONZA (Walkersville, MD). Cells from same passage for both NHLF and DHLF were cultured in Dulbecco’s Modified Eagle’s Medium (DMEM, Corning) supplemented with 10% fetal bovine serum (FBS, Atlanta Biologicals, Norcross, GA), 100 units/ml penicillin-streptomycin, 2 mM L-glutamine (Invitrogen) and maintained at 37 °C in a humidified 5% CO2 environment. Both NHLF and DHLF were used below passage 8 and comparable passages were used in different experiments. Primary mouse LF were isolated from 10-week-old WT and TRPV4 KO mice. Briefly, lungs were removed aseptically, minced into ~1 mm pieces and incubated with agitation in 0.2% trypsin and 0.2% collagenase in DMEM medium supplemented with 10% fetal bovine serum, 100 units/ml penicillin-streptomycin, 2 mM L-glutamine for 30 minutes. The resulting cell suspension was filtered with a cell strainer (40 μm) (BD Biosciences, San Jose, CA) and centrifuged at 500 x g for 5 minutes. Cell pellet was washed, re-suspended and cultured in DMEM medium (10% FBS, 100 units/ml penicillin-streptomycin and 2 mM L-glutamine) in 25 cm2 tissue culture flasks and maintained at 37 °C in a humidified 5% CO2 environment.
Cell activation and treatment
NHLF and/or DHLF cells were pre-treated with inhibitors RN1734 (30 μM), LY294002 (50 μM), NAC (5, 10 mM), DPI (0.5, 1 µM), EHT (30–100 µM) for 30 minutes followed by stimulation with TGFβ1 (2 ng/mL for 48 h) to analyze the expression of α-SMA, FN, PAI-1, and MRTF-A expression. Transfection of isoform-specific siRNA smart pool constructs against TRPV4 from Dharmacon (20 nmol/L) and NOX4 from Qiagen (100 nM) were carried out with siLentFect transfection reagent for 48 h, according to the manufacturer’s protocol.
Determination of extracellular H2O2
Extracellular H2O2 levels were determined by using Amplex Red (Molecular Probes) according to manufacturer’s protocol. Briefly, NHLF (7.5 × 104) were treated with and without TGFβ1 (2 ng/mL) in the presence or absence of inhibitors mentioned above. After treatment, cells were washed twice in Krebs-Ringer phosphate glucose buffer (KRPG) and incubated for 30 minutes with Amplex Red reagent (50 µM) and 0.1 U/mL HRP in KRPG. Fluorescence was measured with excitation and emission at 530 and 590 nm respectively using fluorescence spectrophotometer (Hitachi F-4500) and the data is presented as relative fluorescence units (RFU).
Cell lysates and immunoblotting
After stimulation with the respective agonists, NHLF (7.5 × 104) were lysed with lysis buffer (BD Bioscience, San Jose, CA) supplemented with protease inhibitor cocktail (Roche) and phosphatase inhibitor cocktail (Pierce, Rockford, IL). Immunoblotting was performed as previously described29. Briefly, lysates were subjected to 4–12% SDS-PAGE and transferred to polyvinylidene difluoride membranes. The membranes were blocked and incubated with Abs against α-SMA, FN, MRTF-A and PAI-1 in 1% Tris buffer saline (TBS) 5% dry milk, 0.1% Tween-20) (1:1000) overnight at 4 °C on shaker, and then with secondary Ab. Bands were visualized with enhanced chemiluminiscence (ECL) and protein bands were visualized using an imager (ProteinSimple, San Jose, CA). The blots were stripped and re-probed with Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) Ab (1:25000). Densitometric analysis of the bands on the blots were quantified by AlphaView software (version 3.4, ProteinSimple).
Real-time quantitative PCR
The expressions of α-SMA, collagen 1A1, FN, MRTF-A, SM22, and PAI-1 transcripts were determined with qPCR performed on Light cycler 480 (Roche). Total RNA was isolated from NHLF and DHLF after respective treatments with an E.Z.N.A. Total RNA kit 1 (Omega Bio-Tek, Norcross, Georgia). RNA from tissues was extracted by Trizol-chloroform and was treated with RNase-free DNase (Invitrogen). DNAse contamination was removed using DNA-free DNA Removal Kit (Invitrogen) based on the manufacturer’s instructions. cDNA was synthesized using cDNA synthesis kit from Roche. qPCR was performed using primers mentioned below. Levels of respective genes relative to the GAPDH were analyzed and the ∆ΔCT values were calculated and expressed as relative expression or fold change compared to control. Quality of the RNA, primers and real time PCR reaction was validated using proper controls like no RT control and water control. Real time PCR for each sample was performed in at least triplicate and repeated in three different experiments.
Primers
h NOX4 Qiagen (Hilden, Germany) catalog no. PPH06078A-200
h α-SMA
F: 5′-CGGGACATCAAGGAGAAACT-3′
R: 5′-CCATCAGGCAACTCGTAACT-3′
h COLLAGEN 1 A1
F: 5′-CGATGGATTCCAGTTCGAGTATG-3′ R: 5′-CTTGCAGTGGTAGGTGATGTT-3′
h FN
F: 5′-ACAACACCGAGGTGACTGAGAC-3′
R: 5′-GGACACAACGATGCTTCCTGAG-3′
h SM22
F: 5′-TGGAGATCCCAACTGGTTTAT-3′
R: 5′-CCCATCTGAAGGCCAATG -3′
h TRPV4
F: 5′-TCACTCTCACCGCCTACTACC A-3′
R: 5′-CCCAGTGAAGAGCGTAATGACC-3′
h NOX1
F: 5′-GGTTTTACCGCTCCCAGCAGAA-3′
R: 5′-CTTCCATGCTGAAGCCACGCTT-3′
h NOX2
F: 5′-CTCTGAACTTGGAGACAGGCAAA-3′
R: 5′-CACAGCGTGATGACAACTCCAG-3′
h NOX3
F: 5′-CCTGGAAACACGGATGAGTGAG-3′
R: 5′-CCTCCCATAGAAGGTCTTCTGC-3′
h NOX5
F: 5′-CCACCATTGCTCGCTATGAGTG-3′
R: 5′-GCCTTGAAGGACTCATACAGCC-3′
h GAPDH
F: 5′-TGCACCACCAACTGCTTAGC-3′
R: 5′-GGCATGGACTGTGGTCATGAG-3′
m NOX4
F: 5′-CGGGATTTGCTACTGCCTCCAT-3′
R: 5′-GTGACTCCTCAAATGGGCTTCC-3′
m α-SMA
F: 5′-CCCAGACATCAGGGAGTAATG -3′
R: 5′-GCCGTGTTCTATCGGATACTT -3′
m GAPDH
F: 5′-CTCCCACTCTTCCACCTTCG-3′
R: 5′-CCACCACCCTGTTGCTGTAG-3′
siRNA transfection
NHLF cells were transfected with siGENOME SMART pool (a mix of 4 pre-made siRNA; Dharmacon, Lafayette, CO) of 20 nM TRPV4 specific siRNA to block TRPV4, 100 nM NOX4-specific siRNA (to block NOX4) or non-specific siRNA (negative control). The sequence information for siRNA oligos is given below. Transfection was carried out with siLentFect transfection reagent (Bio-Rad) according to manufacturer’s instructions. Post transfection, cells were treated as mentioned previously19.
h TRPV4- siGENOME SMART pool (Cat# M-004195-00-0005)
Target Sequence 1: GAACCCGUGUGCCAACAUG
Target Sequence 2: CAACCGGCCUAUCCUCUUU
Target Sequence 3: GACCAAAUCUGCGCAUGAA
Target Sequence 4: GCACACCGCCGUACCCUUA
h NOX4- siGENOME SMART pool (Cat# M-010194-00)
Target Sequence 1: GAAUUACAGUGAAGACUUU
Target Sequence 2: CAGGAGGGCUGCUGAAGUA
Target Sequence 3: GGGCUAGGAUUGUGUCUAA
Target Sequence 4: GAUCACAGCCUCUACAUAU
Non-Targeting- siGENOME Pool#2 siRNA (Cat# D-001206-14-05)
Immunofluorescence
After respective treatment, NHLF were fixed with 4% paraformaldehyde/PBS solution, permeabilized in 0.5% Triton X-100 for 15 min, washed twice in PBS, blocked with 10% FBS containing medium. Thereafter, cells were stained for 1 h with α-SMA antibody, followed by PBS washes and incubation with Alexa Fluor 594 goat anti-mouse secondary antibody for 45 minutes. Following secondary antibody, cells are mounted in fluorescence mounting medium containing DAPI. Images were obtained using EVOS fluorescence microscope.
Statistical analysis
Western blots presented are representative of three experiments performed and data are expressed as means ± SEM from at least three experiments except where otherwise indicated. Significance was determined using one-way analysis of variance (ANOVA) and comparisons between the groups were determined by Tukey’s multiple comparisons test (GraphPad Prism). *P < 0.05, **P < 0.01, ***P < 0.001.
Results
TGFβ1-induced ROS mediate NHLF differentiation
To determine if oxidative stress is involved in the differentiation of fibroblasts to myofibroblasts, we stimulated NHLF with H2O2 and analyzed the expression of α-SMA and FN proteins by western blotting. We found that stimulation of NHLF with H2O2 resulted in a significant up-regulation of both α-SMA and FN proteins (Fig. 1A). Since TGFβ1 is the main driver for fibroblast differentiation, we analyzed if TGFβ1 could enhance ROS (H2O2) using the Amplex Red assay. We observed an increase in ROS generation in response to TGFβ1 at 18 h and plateaued (Fig. 1B). We next asked if this ROS generated by TGFβ1 is required for NHLF differentiation. To address this, we pre-treated NHLF with an antioxidant, NAC, stimulated with TGFβ1, and analyzed the expression of ROS, α-SMA and FN proteins. NAC pre-treatment significantly reduced TGFβ1-enhanced ROS (Fig. 1C), α-SMA and FN protein expression (Fig. 1D,E), as well as the incorporation of α-SMA into the stress fibers (supplemental Fig. 1A), suggesting that oxidative stress plays an important role in TGFβ1-induced differentiation of NHLF.
NOX4 is required for TGFβ1 induced NHLF differentiation
We next asked if TGFβ1 mediates fibroblast differentiation through the up-regulation of NOX. We treated NHLF with TGFβ1 for 48 h and then evaluated the expression levels of NOX1-5. We found that TGFβ1 stimulation resulted in significant increase in NOX4 transcript and reduction in NOX1 but had no effect on the expression of NOXs 2, 3 and 5 (Fig. 2A). Further, TGFβ1 promoted a time-dependent upregulation of NOX4, which started at 8 h and plateaued (Fig. 2B). Next, to determine if NOX mediates TGFβ1-induced differentiation, we pre-treated NHLF with a general NOX inhibitor, DPI and examined the levels of α-SMA and FN proteins. DPI pre-treatment significantly inhibited TGFβ1-induced α-SMA and FN protein expression (Fig. 2C,D) as well as the incorporation of α-SMA into the stress fibers (supplemental Fig. 1B). To determine the specific role of NOX4 in TGFβ1-induced differentiation, we knocked down NOX4 in NHLF by NOX4-specific siRNA and analyzed TGFβ1-mediated NHLF differentiation. We found that NOX4-specific siRNA significantly down regulated both basal and TGFβ1-mediated NOX4 expression (Fig. 2G) and NHLF differentiation as evidenced by reduced α-SMA and FN levels (Fig. 2E,F). NOX4 specific siRNA, but not non-specific siRNA, reduced NOX4 expression, confirming the specific down regulation of NOX4 by the NOX4 siRNA oligos used in the experiment (Fig. 2G).
NOX4 mediates TGFβ1-induced MRTF-A activation, fibrotic gene expression, and inhibits matrix degradation
Fibrotic gene expression is regulated by serum responsive factor (SRF) and its co-activators of the myocardin family30. MRTF-A is a mechanosensitive transcription factor, which is known to be activated in response to stress fiber formation via Rho31 and activates fibrotic gene expression. We have previously shown that TGFβ1 enhanced the expression and translocation of MRTF-A to the nucleus in LF19. Since NOX4 is involved in TGFβ1-mediated NHLF differentiation, we investigated if NOX4 regulates TGFβ1-induced MRTF-A, and expression of fibrotic genes. TGFβ1 stimulation significantly enhanced MRTF-A protein expression, which is attenuated by NAC (supplemental Fig. 2A,B), DPI (Fig. 3A,B), and NOX4 siRNA (Fig. 3C,D). Further, we found that TGFβ1 induced higher expression of fibrotic genes including collagen1A1 (Fig. 3E), SM22, and FN (supplemental Fig. 3A,B), which was attenuated by NOX4 siRNA. Matrix accumulation is a balance between matrix synthesis and degradation. Since our results indicated that NOX4 enhances fibrotic gene expression and matrix synthesis in response to TGFβ1, we further speculated if NOX4 also can regulate matrix degradation. Plasmin, which is involved in the degradation of ECM components is activated from plasminogen by tissue-type plasminogen activator (t-PA) or urokinase-type PA (u-PA), and plasminogen activator inhibitor-1 (PAI-1) is a major inhibitor of both t-PA and u-PA32. Since we demonstrated earlier that TGFβ1 increased the expression of PAI-1 at both the transcript and protein levels19, we asked if NOX4 can also regulate PAI-1 expression. Inhibition of NOX4 either pharmacologically by NAC (supplemental Fig. 2C,D), DPI (Fig. 3A,B), or by NOX4 siRNA (Fig. 3F,G) significantly attenuated PAI-1 protein expression.
TRPV4 integrates TGFβ1 and NOX4 signals during fibroblast differentiation
We have previously shown that TRPV4 is critical for TGFβ1-induced NHLF differentiation19, while our current results implicate a strong role for NOX4 in TGFβ1-mediated effects. Therefore, we examined if there is an interaction between TRPV4 and NOX4. To achieve this, we pre-treated NHLF with either TRPV4 inhibitor RN or TRPV4 siRNA, stimulated with TGFβ1 and analyzed NOX4 expression. We observed that TRPV4 inhibition by pharmacological inhibitor RN (Fig. 4A) or siRNA downregulation (Fig. 4B) significantly attenuated TGFβ1-mediated NOX4 expression. TRPV4 siRNA, but not non-specific siRNA, induced TRPV4 inhibition, confirming the specific down regulation of TRPV4 by TRPV4 siRNA oligos (Fig. 4C). While TGFβ1 treatment enhanced NOX4 and α-SMA expression in WT fibroblasts, this response was completely attenuated in TRPV4 KO fibroblasts (Fig. 4D). Further, we found that TRPV4 inhibitor RN significantly inhibited TGFβ1-induced NOX4 activity (ROS generation; Fig. 4E). Taken together, these results demonstrate that TRPV4 regulates NOX4 expression and activity downstream of TGFβ1.
PI3K and Rac regulate TGFβ1-mediated NOX4 expression and function
Next, we investigated the mechanism by which TGFβ1 /TRPV4 axis regulates NOX4. We have demonstrated earlier that TGFβ1 activates PI3K in NHLF and PI3K is required for the translocation of TRPV4 to the membrane and NHLF differentiation19. We found that pre-treatment with PI3K inhibitor LY significantly inhibited TGFβ1-mediated NOX4 expression and ROS generation (Fig. 5A,B). Among several PI3K downstream targets, Rac-1 has been established to transduce PI3K signals to generate ROS in fibroblasts33. Therefore, we pre-treated NHLF with Rac-1 inhibitor EHT, stimulated with TGFβ1, and analyzed NOX4 and fibrotic gene expression. EHT pre-treatment completely inhibited TGFβ1-mediated NOX4 expression (Fig. 5C), H2O2 generation (supplemental Fig. 3C) as well as α-SMA and FN proteins (Fig. 5D,E).
TRPV4/NOX4 axis mediates airway remodeling in asthma
To understand the significance of the TRPV4-NOX pathway in fibroblast differentiation in asthma, we took advantage of fibroblasts isolated from normal (NHLF) and from patient suffering from asthma exacerbation (DHLF) and analyzed NOX4 expression in both cell types. Interestingly, we found NOX4 expression is higher in DHLF compared to NHLF (Fig. 6A). Further, TGFβ1 treatment significantly increased NOX4 expression and differentiation in DHLF compared to NHLF (Fig. 6B). Importantly, siRNA knockdown of either NOX4 or TRPV4, in NHLF and DHLF, significantly attenuated TGFβ1-mediated α-SMA expression (Fig. 6B). To determine the pathophysiological significance of TRPV4/NOX4 axis in asthma, WT and TRPV4 KO mice were subjected to intranasal inhalation of either saline or D. farinae antigen (25 μg), three times a week for five weeks and analyzed immune cells in BAL fluid, goblet cells and NOX4 transcript expression in lung. We observed increased recruitment of lymphocytes and polymorphonuclear leukocytes (PMN) to the lung (Fig. 6C), goblet cell metaplasia (supplemental Fig. 4) only in WT mice, but not TRPV4 KO mice. NOX4 expression was significantly upregulated in response to D. farinae in WT mice compared to saline treated mice (Fig. 6D). In contrast, there was no change in NOX4 expression in response to D. farinae in TRPV4 KO mice (Fig. 6D).
Discussion
Although fibroblast differentiation is critical in physiological airway remodeling, uncontrolled differentiation of fibroblasts to myofibroblasts can lead to lung fibrosis. In fact, lung biopsy samples from several asthmatics reveal enhanced fibroblast numbers compared to normal subjects, which correlated to the thickening of the lamina reticularis3,34. However, the precise molecular mechanism(s) underlying fibroblasts differentiation are still elusive. In parallel to the extensive lung remodeling observed in asthmatic airways, enhanced expression of TGFβ1 was also observed35. Soluble factor, TGFβ1, has been identified as a master regulator for fibroblast to myofibroblast differentiation10,11,12 in vitro and in tissue fibrosis of many organs36,37 via canonical and non-canonical pathways. TGFβ1 signals through TGFβ1 receptor types I and II via SMAD-dependent or SMAD-independent pathways like PI3K, p38 MAPK, focal adhesion kinases, and Rho GTPases to drive myofibroblast differentiation. Although TGFβ1 is a major driver of myofibroblast differentiation, targeting it is not an option to prevent aberrant remodeling due to its pleiotropic nature. This makes it imperative to understand signals downstream of TGFβ for the therapy of fibrotic disorders, including airway remodeling. Apart from soluble factors, an abnormal mechanical environment has been predicted to modify the composition of the ECM in airways14. Interestingly, structural remodeling of the airways has been found in children with recurrent wheezing, regardless of their atopic status38. TRPV4, a mechanosenstive ion channel has been found to regulate pulmonary function in ventilator-induced lung injury39 and airway remodeling19. Although TRPV4 is activated by physical and chemical stimuli (temperature, hypo tonicity, phorbol esters, endocannabinoids, arachidonic acid (AA) and its metabolites, epoxy eicosatrienoic acids (EETs)40,41,42,43, we and others recently demonstrated that TRPV4 is also activated by TGFβ18,19,23 and play a vital role in lung remodeling. Intriguingly, TRPV4 gene polymorphisms have been shown to influence the development of osmotic airway hyperresponsiveness in patients with bronchial asthma16. However, the mechanism through which TRPV4 is activated or whether and how TRPV4 facilitates fibroblast differentiation and matrix remodeling, specifically in asthma, is still elusive. Besides soluble and mechanical signals, enhanced ROS production is well documented in asthma, and the airways of asthmatics produce more ROS than subjects with healthy lungs44,45,46. TGFβ1 is known to promote myofibroblast differentiation through ROS47, and high levels of superoxides are generated by NOX20. Specifically, NOX4 isoform that is transcriptionally regulated and constitutively active was found to mediate contractility, matrix production, and α-SMA expression. Although NHLF express NOX1, 4 and 5 transcripts, we found significant up-regulation of only NOX4 in response to TGFβ1. TGFβ1 has been shown to induce NOX4 expression in lung mesenchymal cells via SMAD-3-dependent pathway and NOX4-dependent ROS generation is required for TGFβ1- induced myofibroblast differentiation, ECM production and contractility48. Since both mechanical factors and ROS are crucial players in regulating myofibroblast differentiation and airway remodeling, we explored if there exits an interaction between TRPV4 and NOX downstream of TGFβ1. Our results demonstrated that TGFβ1 enhances ROS generation and NOX4 expression. Unfortunately, we could not validate NOX4 expression at protein level due to the non-specific NOX4 Abs currently available. Since enhanced ECM build-up is a characteristic of lung remodeling because of fibroblast differentiation, we asked if NOX4 contributes to increase in matrix synthesis, or reduction in matrix degradation, or both. Fibrotic gene expression is regulated by the co-activators of the myocardin family. Upon activation, MRTF-A translocates to the nucleus, associates with SRF CC(A/T)6GG (CArG box) present in the promoter of target genes, including α-SMA. Interestingly, mechanical forces are known to stimulate translocation of MRTF-A transcription factor into the nucleus30. NOX4 has been shown earlier to regulate fibrotic gene expression and matrix synthesis through MRTF-A in kidney epithelial cells49. In accordance, we found that NOX4 mediates TGFβ1-induced fibrotic gene expression (collagen1A1, α-SMA, FN, and SM-22) via activation of MRTF-A during fibroblast differentiation. Further, we found that NOX4 also contributes to enhanced ECM by modulating matrix degradation (by increasing PAI-1 expression). Although ROS have been implicated in TRPV4-induced neuronal signaling50, the TRPV4-NOX interaction has not been reported thus far. Intriguingly, we found that knocking down TRPV4 attenuated NOX4 induction by TGFβ1, suggesting that TRPV4 acts upstream of NOX4. Further, PI3K inhibitor LY, which significantly inhibited TRPV4 translocation to the membrane19, also attenuated NOX4 expression and activity, suggesting that both TRPV4 and NOX4 are downstream of PI3K. We further explored how PI3K regulates NOX4. In fibroblasts, PI3K mediates PDGF-dependent ROS production via Rac-133. Therefore, we wondered if PI3K mediates ROS production via Rac-1 downstream of TGFβ1 as well. Interestingly, Rac inhibition significantly inhibited TGFβ1-mediated NOX4 expression, activity, and fibrotic gene expression. NOX4 has been implicated in relaying pro-fibrotic responses to TGFβ47, and pharmacological inhibition or knockdown of the NOX4 transcript has been shown to suppress matrix synthesis and experimentally induce lung fibrosis in mice48. However, the role of NOX4 in asthma is still elusive. Our results demonstrated that at basal levels, LF isolated from asthma patients (DHLF) exhibit higher expression of NOX4 and α-SMA compared to fibroblasts from normal (NHLF) subjects, which were significantly increased in response to TGFβ1. Importantly, we found that NOX4 expression is highly upregulated in experimentally induced asthma model (D. farinae-challenged mice) compared to controls, suggesting an essential role for NOX4 in airway remodeling. We had established earlier that TRPV4 KO mice were protected from D. farinae-induced lung remodeling during asthma and its concomitant increase in TGFβ lung transcripts19. Finally, we found that D. farinae challenge failed to increase expression of NOX4 and a-SMA as well as pathological airway remodeling in TRPV4 KO mice, suggesting that TRPV4 relays fibrotic responses via NOX4.
In this study, we demonstrated that mechanosensitive ion channel TRPV4 integrates growth factor (TGFβ1) and redox (NOX4) signaling during lung fibroblast differentiation and airway remodeling in asthma (Fig. 7). We concluded this based on the findings that (1) TGFβ1 induced lung fibroblast differentiation through NOX4-dependent generation of ROS, (2) pharmacological or siRNA downregulation of NOX4 significantly attenuated ROS generation, MRTF-A activation, and fibroblast differentiation, (3) pharmacological inhibition or siRNA downregulation of TRPV4 significantly inhibited NOX4 expression and fibroblast differentiation, and (5) NOX4 is upregulated in fibroblasts from asthmatic subjects and airway remodeling in experimentally induced asthma, and this response is attenuated in TRPV4 KO mice. In conclusion, our results suggest that targeting TRPV4/NOX4 signaling may provide a new therapy for lung remodeling in asthma in situations where treatments focused solely on steroids or other conventional treatments have proven ineffective.
References
Elias, J. A., Zhu, Z., Chupp, G. & Homer, R. J. Airway remodeling in asthma. J. Clin. Invest. 104, 1001–1006 (1999).
Tang, M. L., Wilson, J. W., Stewart, A. G. & Royce, S. G. Airway remodelling in asthma: current understanding and implications for future therapies. Pharmacol. Ther. 112, 474–488 (2006).
Benayoun, L., Druilhe, A., Dombret, M. C., Aubier, M. & Pretolani, M. Airway structural alterations selectively associated with severe asthma. Am. J. Respir. Crit. Care Med. 167, 1360–1368 (2003).
Bergeron, C., Tulic, M. K. & Hamid, Q. Airway remodelling in asthma: from benchside to clinical practice. Can. respiratory J. 17, e85–93, https://doi.org/10.1155/2010/318029 (2010).
Boxall, C., Holgate, S. T. & Davies, D. E. The contribution of transforming growth factor-beta and epidermal growth factor signalling to airway remodelling in chronic asthma. Eur. Respir. J. 27, 208–229 (2006).
Holgate, S. T. Pathogenesis of asthma. Clin. Exp. Allergy 38, 872–897 (2008).
Huang, J., Olivenstein, R., Taha, R., Hamid, Q. & Ludwig, M. Enhanced proteoglycan deposition in the airway wall of atopic asthmatics. Am. J. Respir. Crit. Care Med. 160, 725–729 (1999).
Roche, W. R., Beasley, R., Williams, J. H. & Holgate, S. T. Subepithelial fibrosis in the bronchi of asthmatics. Lancet 1, 520–524 (1989).
Wilson, J. W. & Li, X. The measurement of reticular basement membrane and submucosal collagen in the asthmatic airway. Clin. Exp. Allergy 27, 363–371 (1997).
Hinz, B. Formation and function of the myofibroblast during tissue repair. J. Invest. Dermatol. 127, 526–537 (2007).
Hinz, B. et al. The myofibroblast: one function, multiple origins. Am. J. Pathol. 170, 1807–1816 (2007).
Hinz, B. et al. Recent developments in myofibroblast biology: paradigms for connective tissue remodeling. Am. J. Pathol. 180, 1340–1355, https://doi.org/10.1016/j.ajpath.2012.02.004 (2012).
Schmidt-Weber, C. B. & Blaser, K. Regulation and role of transforming growth factor-beta in immune tolerance induction and inflammation. Curr. Opin. Immunol. 16, 709–716 (2004).
Wang, J. H. & Thampatty, B. P. An introductory review of cell mechanobiology. Biomech. Model. Mechanobiol. 5, 1–16 (2006).
Balakrishna, S. et al. TRPV4 inhibition counteracts edema and inflammation and improves pulmonary function and oxygen saturation in chemically induced acute lung injury. Am. J. Physiol. Lung Cell Mol. Physiol 307, L158–172, https://doi.org/10.1152/ajplung.00065.2014 (2014).
Naumov, D. E., Kolosov, V. P., Perelman, J. M. & Prikhodko, A. G. Influence of TRPV4 gene polymorphisms on the development of osmotic airway hyperresponsiveness in patients with bronchial asthma. Doklady. Biochem. biophysics 469, 260–263, https://doi.org/10.1134/S1607672916040074 (2016).
Adapala, R. K. et al. TRPV4 channels mediate cardiac fibroblast differentiation by integrating mechanical and soluble signals. J. Mol. Cell Cardiol. 54, 45–52 (2013).
Rahaman, S. O. et al. TRPV4 mediates myofibroblast differentiation and pulmonary fibrosis in mice. J. Clin. Invest. 124, 5225–5238, https://doi.org/10.1172/JCI75331 (2014).
Gombedza, F. et al. Mechanosensitive transient receptor potential vanilloid 4 regulates Dermatophagoides farinae-induced airway remodeling via 2 distinct pathways modulating matrix synthesis and degradation. FASEB J. 31, 1556–1570, https://doi.org/10.1096/fj.201601045R (2017).
Erzurum, S. C. New Insights in Oxidant Biology in Asthma. Ann. Am. Thorac. Soc. 13(Suppl 1), S35–39, https://doi.org/10.1513/AnnalsATS.201506-385MG (2016).
Amara, N. et al. NOX4/NADPH oxidase expression is increased in pulmonary fibroblasts from patients with idiopathic pulmonary fibrosis and mediates TGFbeta1-induced fibroblast differentiation into myofibroblasts. Thorax 65, 733–738, https://doi.org/10.1136/thx.2009.113456 (2010).
Sampson, N. et al. ROS signaling by NOX4 drives fibroblast-to-myofibroblast differentiation in the diseased prostatic stroma. Mol. Endocrinol. 25, 503–515, https://doi.org/10.1210/me.2010-0340 (2011).
Adapala, R. K. et al. Activation of mechanosensitive ion channel TRPV4 normalizes tumor vasculature and improves cancer therapy. Oncogene 35, 314–322, https://doi.org/10.1038/onc.2015.83 (2016).
Bagher, P. et al. Low intravascular pressure activates endothelial cell TRPV4 channels, local Ca2+ events, and IKCa channels, reducing arteriolar tone. Proc. Natl Acad. Sci. USA 109, 18174–18179 (2012).
Patel, S. et al. Rac-GTPase promotes fibrotic TGF-beta1 signaling and chronic kidney disease via EGFR, p53, and Hippo/YAP/TAZ pathways. FASEB J. 33, 9797–9810, https://doi.org/10.1096/fj.201802489RR (2019).
Conte, E. et al. Inhibition of PI3K prevents the proliferation and differentiation of human lung fibroblasts into myofibroblasts: the role of class I P110 isoforms. PLoS One 6, e24663.
Paruchuri, S., Broom, O., Dib, K. & Sjolander, A. The pro-inflammatory mediator leukotriene D4 induces phosphatidylinositol 3-kinase and Rac-dependent migration of intestinal epithelial cells. J. Biol. Chem. 280, 13538–13544 (2005).
Murphy-Marshman, H. et al. Antioxidants and NOX1/NOX4 inhibition blocks TGFbeta1-induced CCN2 and alpha-SMA expression in dermal and gingival fibroblasts. PLoS One 12, e0186740, https://doi.org/10.1371/journal.pone.0186740 (2017).
Paruchuri, S. et al. (4) activates MAPK through a Ras-independent but PKCepsilon-dependent pathway in intestinal epithelial cells. J. Cell Sci. 115, 1883–1893 (2002).
Zhao, X. H. et al. Force activates smooth muscle alpha-actin promoter activity through the Rho signaling pathway. J. Cell Sci. 120, 1801–1809, https://doi.org/10.1242/jcs.001586 (2007).
Zhou, Y. et al. Inhibition of mechanosensitive signaling in myofibroblasts ameliorates experimental pulmonary fibrosis. J. Clin. Invest. 123, 1096–1108 (2013).
Ghosh, A. K. & Vaughan, D. E. PAI-1 in tissue fibrosis. J. Cell Physiol. 227, 493–507 (2012).
Baumer, A. T. et al. Phosphatidylinositol 3-kinase-dependent membrane recruitment of Rac-1 and p47phox is critical for alpha-platelet-derived growth factor receptor-induced production of reactive oxygen species. J. Biol. Chem. 283, 7864–7876, https://doi.org/10.1074/jbc.M704997200 (2008).
Hoshino, M., Nakamura, Y. & Sim, J. J. Expression of growth factors and remodelling of the airway wall in bronchial asthma. Thorax 53, 21–27 (1998).
Minshall, E. M. et al. Eosinophil-associated TGF-beta1 mRNA expression and airways fibrosis in bronchial asthma. Am. J. Respir. Cell Mol. Biol. 17, 326–333 (1997).
Biernacka, A., Dobaczewski, M. & Frangogiannis, N. G. TGF-beta signaling in fibrosis. Growth Factors 29, 196–202, https://doi.org/10.3109/08977194.2011.595714 (2011).
Wynn, T. A. & Ramalingam, T. R. Mechanisms of fibrosis: therapeutic translation for fibrotic disease. Nat. Med. 18, 1028–1040 (2012).
Turato, G. et al. Nonatopic children with multitrigger wheezing have airway pathology comparable to atopic asthma. Am. J. Respir. Crit. Care Med. 178, 476–482 (2008).
Hamanaka, K. et al. TRPV4 channels augment macrophage activation and ventilator-induced lung injury. Am. J. Physiol. Lung Cell Mol. Physiol 299, L353–362, https://doi.org/10.1152/ajplung.00315.2009 (2010).
Liedtke, W. Role of TRPV ion channels in sensory transduction of osmotic stimuli in mammals. Exp. Physiol. 92, 507–512, https://doi.org/10.1113/expphysiol.2006.035642 (2007).
Liedtke, W. TRPV channels’ role in osmotransduction and mechanotransduction. Handbook of experimental pharmacology, 473-487, https://doi.org/10.1007/978-3-540-34891-7_28 (2007).
Nilius, B., Vriens, J., Prenen, J., Droogmans, G. & Voets, T. TRPV4 calcium entry channel: a paradigm for gating diversity. Am. J. Physiol. Cell Physiol 286, C195–205, https://doi.org/10.1152/ajpcell.00365.2003 (2004).
Vriens, J. et al. Cell swelling, heat, and chemical agonists use distinct pathways for the activation of the cation channel TRPV4. Proc. Natl Acad. Sci. USA 101, 396–401, https://doi.org/10.1073/pnas.0303329101 (2004).
Busse, W., Elias, J., Sheppard, D. & Banks-Schlegel, S. Airway remodeling and repair. Am. J. Respir. Crit. Care Med. 160, 1035–1042, https://doi.org/10.1164/ajrccm.160.3.9902064 (1999).
Calhoun, W. J., Reed, H. E., Moest, D. R. & Stevens, C. A. Enhanced superoxide production by alveolar macrophages and air-space cells, airway inflammation, and alveolar macrophage density changes after segmental antigen bronchoprovocation in allergic subjects. Am. Rev. Respir. Dis. 145, 317–325, https://doi.org/10.1164/ajrccm/145.2_Pt_1.317 (1992).
Hoshino, T. et al. Redox-regulated mechanisms in asthma. Antioxid. redox Signal. 10, 769–783, https://doi.org/10.1089/ars.2007.1936 (2008).
Jiang, F., Liu, G. S., Dusting, G. J. & Chan, E. C. NADPH oxidase-dependent redox signaling in TGF-beta-mediated fibrotic responses. Redox Biol. 2, 267–272, https://doi.org/10.1016/j.redox.2014.01.012 (2014).
Hecker, L. et al. NADPH oxidase-4 mediates myofibroblast activation and fibrogenic responses to lung injury. Nat. Med. 15, 1077–1081, https://doi.org/10.1038/nm.2005 (2009).
Rozycki, M. et al. Myocardin-related Transcription Factor Regulates Nox4 Protein Expression: LINKING CYTOSKELETAL ORGANIZATION TO REDOX STATE. J. Biol. Chem. 291, 227–243, https://doi.org/10.1074/jbc.M115.674606 (2016).
Hong, Z. et al. Enhanced Oxidative Stress Is Responsible for TRPV4-Induced Neurotoxicity. Front. Cell. Neurosci. 10, 232, https://doi.org/10.3389/fncel.2016.00232 (2016).
Acknowledgements
This work was supported by James Foght Assistant Professor support and NIH (R15HL133918 and R01AI144115).
Author information
Authors and Affiliations
Contributions
N. Al-Azzam, L. Teegala, S. Pokhrel, performed experiments, analyzed the data and edited the manuscript; S. Ghebreigziabher, T. Chachkovskyy, S. Thodeti, I. Gavilanes, K. Covington performed experiments and analyzed the data; C. K.Thodeti provided TRPV4 KO mice, designed some of the experiments, and edited the manuscript; and S. Paruchuri designed experiments, performed research, analyzed and interpreted data, and wrote the manuscript.
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing interests.
Additional information
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Supplementary information
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
About this article
Cite this article
Al-Azzam, N., Teegala, L.R., Pokhrel, S. et al. Transient Receptor Potential Vanilloid channel regulates fibroblast differentiation and airway remodeling by modulating redox signals through NADPH Oxidase 4. Sci Rep 10, 9827 (2020). https://doi.org/10.1038/s41598-020-66617-2
Received:
Accepted:
Published:
DOI: https://doi.org/10.1038/s41598-020-66617-2
- Springer Nature Limited
This article is cited by
-
Mechanosensitive TRPV4 channel guides maturation and organization of the bilayered mammary epithelium
Scientific Reports (2024)
-
Advances in TRP channel drug discovery: from target validation to clinical studies
Nature Reviews Drug Discovery (2022)
-
Animal study of a newly designed metal airway brachytherapy stent loaded with radioactive 125I seeds
Journal of Cancer Research and Clinical Oncology (2022)
-
Six Decades of History of Hypertension Research at the University of Toledo: Highlighting Pioneering Contributions in Biochemistry, Genetics, and Host-Microbiota Interactions
Current Hypertension Reports (2022)